S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:MYOK

MyoKardia (MYOK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$224.91
$224.91
50-Day Range
$222.81
$224.91
52-Week Range
$42.65
$225.00
Volume
N/A
Average Volume
752,969 shs
Market Capitalization
$11.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MYOK stock logo

About MyoKardia Stock (NASDAQ:MYOK)

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.

MYOK Stock News Headlines

Astria Therapeutics expands board with new director
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
FULC Fulcrum Therapeutics, Inc.
Cytokinetics: CEO Talks Down Buyout Prospects
Q4 2023 Fulcrum Therapeutics Inc Earnings Call
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Why LianBio Stock Is Ripping Higher Today
Why Is LianBio (LIAN) Stock Up 130% Today?
Why LianBio Stock Is Skyrocketing Today
Cutera Names Taylor Harris As CEO, Shares Gain
See More Headlines
Receive MYOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2020
Today
4/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYOK
Fax
N/A
Employees
318
Year Founded
N/A

Profitability

Net Income
$-276,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.56 million
Book Value
$8.79 per share

Miscellaneous

Free Float
N/A
Market Cap
$11.99 billion
Optionable
Optionable
Beta
1.84
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Tassos Anastasios E. Gianakakos (Age 47)
    Pres, CEO & Director
    Comp: $987.02k
  • Mr. Taylor C. Harris (Age 44)
    Chief Financial Officer
    Comp: $604.47k
  • Dr. Robert S. McDowell (Age 62)
    Chief Scientific Officer
    Comp: $579.19k
  • Mr. Jake B. Bauer (Age 41)
    Chief Bus. Officer
    Comp: $547.2k
  • Mr. William C. Fairey Jr. (Age 54)
    Chief Commercial Officer & Exec. VP
    Comp: $905.02k
  • Dr. Leslie Leinwand
    Co-Founder
  • Dr. Christine E. Seidman (Age 67)
    Co-Founder
  • Dr. Jonathan G. Seidman
    Co-Founder
  • Dr. James A. Spudich (Age 78)
    Co-Founder
  • Michelle Corral
    Exec. Director of Corp. Communications & Investor Relations

MYOK Stock Analysis - Frequently Asked Questions

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) announced its earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.16.

What other stocks do shareholders of MyoKardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and RTX (RTX).

This page (NASDAQ:MYOK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners